Search results
The CEO behind the world's biggest science and engineering fair says the biggest mistake parents...
Business Insider via Yahoo News· 2 days agoMaya Ajmera, Grace Sun, and Christina Chan on stage at this year's Regeneron ISEF ceremony, where...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating...
FOX 23 News Albany· 9 hours agoBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing...
US FDA approves two biosimilars for blockbuster eye drug Eylea
Reuters via AOL· 4 days agoRegeneron has filed lawsuits against companies such as Amgen and Biocon, which are seeking to bring...
FDA Approves First Two Interchangeable EYLEA® Biosimilars – Biocon’s Yesafili™ (aflibercept-jbvf)...
JD Supra· 3 days agoOn May 20, 2024, the FDA approved the first two interchangeable biosimilars of Regeneron’s EYLEA® (aflibercept) – Biocon Biologics and Mylan’s...
With analysts seeing a likely US recession, here are 4 recession proof stocks to consider | Invezz...
Invezz· 3 days agoAt the beginning of 2024, Citigroup chief US economist predicted in a CNBC interview that the USA...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 6 days agoNEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zymeworks Inc. (NASDAQ: ...
US FDA approves Biocon unit’s biosimilar to blockbuster eye drug Eylea
KFGO· 4 days ago(Reuters) - The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to ...
...COPD Trial Presented at ATS and Published in The New England Journal of Medicine - Regeneron...
Benzinga· 4 days agoNOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at...
Benzinga· 4 days agoDupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International...
The Record Gazette· 7 days agoCongratulations to Krish Pai, Grace Sun and Michelle Wei - the top winners at the 2024 Regeneron...